The transition from either epidemiological observation or the bench to rigorously tested
clinical trials in patients with Alzheimer's disease is crucial in understanding which …

Alzheimer's disease (AD) is the most common type of dementia in the elderly. Several
hypotheses emerged from AD pathophysiological mechanisms. However, no neuronal …

Aduhelm is an immunotherapy from Biogen that induces clearance of Alzheimer, s disease
(AD)-associated βamyloid deposits in the brain. Aduhelm was originally developed at the …

Alzheimer's disease (AD) is the most common cause of dementia. The pathophysiology of
this disease is characterized by the accumulation of amyloid-β, leading to the formation of …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most
common cause for dementia. There are many hypotheses about AD, including abnormal …

Dementia is increasingly being recognized as one of the most important medical problems
in the elderly. As most pharmacological research within the field of dementia is focused on …

Alzheimer's disease (AD) is a neurodegenerative disorder and is identified as the most
common cause for dementia. Despite huge global economic burden and the impact on the …

The foundation of current Alzheimer's disease (AD) treatment involves pharmacological and
nonpharmacological management and care planning predicated on patient-centered …

Alzheimer's disease (AD) is the most common cause of dementia. It is characterized by
cognitive decline and progressive memory loss. The aim of this review was to update the …

Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease, and
corresponds to the most common cause of dementia worldwide. Although not fully …